Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2026
0mins
Source: Yahoo Finance
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 80.970
Low
102.00
Averages
111.76
High
120.00
Current: 80.970
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy
- FDA Breakthrough Designation: Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for AVIM Therapy, covering over 7.7 million adults with uncontrolled hypertension despite medication, marking a significant advancement in cardiovascular treatment.
- Clinical Trial Support: This designation aligns with the ongoing BACKBEAT global pivotal trial aimed at evaluating the safety and efficacy of AVIM Therapy in hypertensive patients, further strengthening the strategic partnership with Medtronic.
- Reimbursement Pathway Optimization: The Breakthrough Device Designation supports favorable reimbursement pathways, including New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payments, which will facilitate timely patient access and provider adoption.
- Significant Market Potential: As a bioelectronic treatment designed to substantially lower blood pressure in hypertensive patients, AVIM Therapy is expected to generate multi-billion-dollar market opportunities for Orchestra BioMed, further solidifying its leadership position in the medical device market.
See More
Bidding War Intensifies in AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, reflecting strong demand for AI technologies in healthcare.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, highlighting the growing importance of AI in medical institutions.
- Innovation Recognition: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, marking a significant achievement in clinical application and reinforcing its competitive position among small-cap medtech companies.
- International Collaboration Expansion: VentriPoint's collaboration with the Health Division of the Montecristo Group aims to roll out VMS+™ across Costa Rica's public and private hospital networks, showcasing its potential for market expansion in Latin America, while also partnering with First Light Health to provide cardiac diagnostics to Indigenous and remote communities in Canada.
See More
Bidding War Intensifies for AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, intensifying industry competition.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, reflecting a heightened emphasis on AI technology in healthcare institutions.
- Recognition of Technological Innovation: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, underscoring the effectiveness of its technology in clinical applications and further solidifying its competitive position in the medical imaging sector.
- International Collaboration Expansion: VentriPoint's partnerships with the Montecristo Group and First Light Health aim to promote cardiac diagnostics through its VMS+™ platform in Costa Rica and remote communities in Canada, demonstrating its potential for global market expansion and commitment to social responsibility.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy
- FDA Breakthrough Designation: Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for AVIM Therapy, covering over 7.7 million adults with uncontrolled hypertension despite medication, marking a significant advancement in cardiovascular treatment.
- Clinical Trial Support: This designation aligns with the ongoing BACKBEAT global pivotal trial aimed at evaluating the safety and efficacy of AVIM Therapy in hypertensive patients, further strengthening the strategic partnership with Medtronic.
- Reimbursement Pathway Optimization: The Breakthrough Device Designation supports favorable reimbursement pathways, including New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payments, which will facilitate timely patient access and provider adoption.
- Significant Market Potential: As a bioelectronic treatment designed to substantially lower blood pressure in hypertensive patients, AVIM Therapy is expected to generate multi-billion-dollar market opportunities for Orchestra BioMed, further solidifying its leadership position in the medical device market.
See More
Bidding War Intensifies in AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, reflecting strong demand for AI technologies in healthcare.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, highlighting the growing importance of AI in medical institutions.
- Innovation Recognition: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, marking a significant achievement in clinical application and reinforcing its competitive position among small-cap medtech companies.
- International Collaboration Expansion: VentriPoint's collaboration with the Health Division of the Montecristo Group aims to roll out VMS+™ across Costa Rica's public and private hospital networks, showcasing its potential for market expansion in Latin America, while also partnering with First Light Health to provide cardiac diagnostics to Indigenous and remote communities in Canada.
See More
Bidding War Intensifies for AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, intensifying industry competition.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, reflecting a heightened emphasis on AI technology in healthcare institutions.
- Recognition of Technological Innovation: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, underscoring the effectiveness of its technology in clinical applications and further solidifying its competitive position in the medical imaging sector.
- International Collaboration Expansion: VentriPoint's partnerships with the Montecristo Group and First Light Health aim to promote cardiac diagnostics through its VMS+™ platform in Costa Rica and remote communities in Canada, demonstrating its potential for global market expansion and commitment to social responsibility.
See More
